Pfizer has received approval from the US Food and Drug Administration (FDA) for Geodon capsules as part of a combination maintenance treatment for bipolar disorder in adults.
The FDA has approved Geodon for the treatment of bipolar 1 disorder as an adjunct to lithium or valproate in adults.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Bipolar disorder affects about 5.7 million adults in the US and needs lifelong treatment and management.
Geodon is also FDA-approved for the treatment of acute manic and mixed episodes associated with bipolar disorder, with or without psychotic features, and for the treatment of schizophrenia.
